Diagnosing an oxidative stress (OS) in companion animals comprises screening a bodily fluid sample to detect the presence of an OS biomarker, selectively isoprostane and antioxidants, HODE, microRNAs, TAC, GSH, MDA, and TNF-alpha. The sample can be saliva.

The aspects of the disclosed embodiments relate to method for determining a likelihood of an inflammatory gastrointestinal tract disease. The method includes diluting a biological sample of a human subject and contacting it with 8-anilinonaphthalene-1-sulfonic acid as modulating agent and further with a reagent, said reagent comprising a peroxidase enzyme and a label selected from a europium chloride and terbium chloride. The sample is incubated and excited, and the time-resolved luminescence signal of the label in the sample is measured. If the luminescence signal is at least 112% higher than for a control sample from a human so subject without of an inflammatory intestine disease, an increased likelihood of an inflammatory intestine disease of the human subject is determined.

The present application relates to the use of compositions comprising a live C. acnes strain secreting RoxP (radical oxygenase of Propionibacterium acnes) and compositions comprising RoxP or a biologically active variant or fragment thereof for treating or preventing oxidative stress-associated skin diseases or for preventing or reducing skin ageing. The application further relates to method for diagnosing oxidative stress-associated skin disease in a subject or for determining the benefit a subject would receive from administration of RoxP or a live C. acnes strain secreting RoxP, the methods comprising determining the quantity of RoxP or the quantity of C. acnes in a skin sample from the subject.

A fluorescent protein sensor capable of quantitatively measuring oxidation degree of methionine residues of a specific protein, and a use thereof. Specifically, a fluorescent biosensor recombinant protein in which an MsrB protein, a cpYFP protein, a thioredoxin 3 protein, a linker protein and a G protein are linked in this order, and which is capable of quantitatively measuring the oxidation degree of methionine residues of a target protein; a fluorescent biosensor comprising same; a method for measuring oxidation degree of methionine residues of a target protein; and an information providing method for diagnosis of oxidative stress-associated diseases; and a method for screening for a therapeutic agent for oxidative stress-associated diseases. A recombinant protein for a fluorescent biosensor for accurately and quantitatively measuring, through the detection of a specific change in fluorescence, oxidation degree of methionine residues of a specific protein, but not all proteins, even in a mixed biological sample.

Provided herein are methods of detecting or determining aging and/or oxidative damage in tissue, including placental tissue, skin, kidney and brain tissue. One embodiment provides a method for detecting or determining aging in body tissue, comprising measuring one or more markers of aldehyde oxidase 1 (AOX1) expression or activity in a biological sample, wherein the level of AOX1 expression or activity, or of the one or more markers, is indicative of aging in the tissue. Also provided herein are methods of treating a disease or condition associated with ageing or oxidative damage in one or more cells or tissues, comprising administering to a subject in need thereof an inhibitor of AOX1.

Provided is, as an attempt to realize a method for measuring oxidative stress in human body fluids, a means for measuring reactive oxygen species containing a color indicator that detects the amount of reactive oxygen species present in the human body by causing a color change through reaction with malondialdehyde present in the urine or blood. The detection means has advantages of detecting malondialdehyde (MDA) present at a low concentration in a sample (urine or blood) and exhibiting excellent discrimination owing to high detection sensitivity.

The present disclosure provides an in vitro method of generating bovine monocyte-derived macrophages from monocytes that produce nitric oxide and use as an indicator of innate immune response potential. The culture system includes culturing bovine monocytes in serum-free media supplemented with granulocyte-macrophage stimulating factor (GM-CSF) to generate monocyte-derived macrophages that produce nitric oxide.

Managing and treating elevated OS biomarkers in mammals such as companion animals with at least one of the supplements alpha-lipoic acid, carnitine, co-enzyme Q-10, ginger, green tea, licorice, milk thistle, garlic, honey. resveratrol, soybeans, tomatoes, turmeric, vitamin D, vitamin E or selenium. Diagnosing an oxidative stress (OS) in a mammal comprises collecting a sample; screening the sample to detect the presence of an OS biomarker, selectively isoprostane and other antioxidants such as HODE microRNAs. TAC: GSH, MDA, and TNF-alpha. The sample can be saliva.

The invention relates to a method for in vitro investigating mitochondrial replication dysfunction in a biological sample removed from a subject susceptible of suffering from physiological ageing or physiopathological conditions related to physiological ageing, or physiopathological ageing or associated symptoms or conditions, in particular premature ageing or accelerated ageing, or of a progeroid syndrome, such as Cockayne syndrome (CS), or neurodegenerative disorders or symptoms thereof, in which the levels of at least one species selected in the group of: POLG1 protein, POLG1 RNA, POLG2 protein, protease(s) which have POLG as a target, in particular serine protease(s) such as HTRA3 protein, HTRA2 protein and, HTRA3 RNA or HTRA2 RNA, or any combination of these species, are investigated. The invention also relates to kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptoms and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s) having relevance for the symptoms discussed herein.

The disclosure relates to methods of preventing or treating age-related diseases or conditions in a subject. The method comprises targeting the kynurenine pathway.